Menu

NEW YORK (GenomeWeb) — PredictImmune announced today that it has received a £100,000 ($126,368) grant from Innovate UK to investigate the use of its PredictSure IBD inflammatory bowel disease test to guide patient treatment decisions.

This webinar will discuss background and clinical genomics of NTRK fusion detection in cancer. NTRK fusions are the focus of new therapeutic options, but clonal and subclonal lesions are notoriously difficult to detect.